(LIVN) LivaNova - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 4.056m USD | Total Return: 71.3% in 12m

Heart-Lung Machines, Oxygenators, Vagus Nerve Stimulators, Autotransfusion
Total Rating 67
Safety 40
Buy Signal 1.18
Medical Devices
Industry Rotation: +5.3
Market Cap: 4.06B
Avg Turnover: 54.1M
Risk 3d forecast
Volatility37.3%
VaR 5th Pctl5.56%
VaR vs Median-11.1%
Reward TTM
Sharpe Ratio1.63
Rel. Str. IBD76.4
Rel. Str. Peer Group83.5
Character TTM
Beta1.056
Beta Downside1.329
Hurst Exponent0.490
Drawdowns 3y
Max DD47.23%
CAGR/Max DD0.42
CAGR/Mean DD1.25
EPS (Earnings per Share) EPS (Earnings per Share) of LIVN over the last years for every Quarter: "2021-03": 0.35, "2021-06": 0.52, "2021-09": 0.68, "2021-12": 0.57, "2022-03": 0.48, "2022-06": 0.53, "2022-09": 0.58, "2022-12": 0.81, "2023-03": 0.43, "2023-06": 0.78, "2023-09": 0.73, "2023-12": 0.87, "2024-03": 0.73, "2024-06": 0.93, "2024-09": 0.9, "2024-12": 0.81, "2025-03": 0.88, "2025-06": 1.05, "2025-09": 1.11, "2025-12": 0.86, "2026-03": 0.98,
EPS CAGR: 16.77%
EPS Trend: 98.1%
Last SUE: 1.04
Qual. Beats: 1
Revenue Revenue of LIVN over the last years for every Quarter: 2021-03: 247.603, 2021-06: 264.483, 2021-09: 253.215, 2021-12: 270.064, 2022-03: 240.175, 2022-06: 254.151, 2022-09: 252.605, 2022-12: 274.874, 2023-03: 263.418, 2023-06: 293.882, 2023-09: 286.113, 2023-12: 310.132, 2024-03: 294.912, 2024-06: 318.575, 2024-09: 318.12, 2024-12: 321.83, 2025-03: 316.855, 2025-06: 352.524, 2025-09: 357.8, 2025-12: 360.855, 2026-03: 362.258,
Rev. CAGR: 9.94%
Rev. Trend: 99.6%
Last SUE: 4.00
Qual. Beats: 15

Warnings

Altman Z'' -1.14 < 1.0 - financial distress zone

Tailwinds

Idiosyncratic Leader, Garp

Description: LIVN LivaNova

LivaNova PLC (LIVN) is a London-based medical technology firm specializing in Cardiopulmonary and Neuromodulation solutions. The company manufactures critical life-support equipment, including heart-lung machines and oxygenators, alongside implantable VNS Therapy Systems designed to treat drug-resistant epilepsy and clinical depression. Its commercial model utilizes a mix of direct sales and independent distributors to reach specialized healthcare providers across North America, Europe, and Asia.

The medical device sector is characterized by high barriers to entry due to stringent regulatory approval processes and the technical complexity of implantable electronics. LivaNova’s business model relies on a razor-and-blade strategy, where the initial installation of surgical hardware creates a recurring stream of revenue through the sale of disposables and replacement pulse generators. The company is currently expanding its portfolio through clinical trials for obstructive sleep apnea treatments.

Investors can further analyze these market dynamics and valuation metrics by visiting ValueRay. Given the specialized nature of neurostimulation, the company’s long-term growth is closely tied to its ability to secure insurance reimbursement and expand clinical indications for its proprietary technology.

Headlines to Watch Out For
  • VNS Therapy adoption rates drive Neuromodulation segment revenue growth
  • Global cardiac surgery volumes dictate cardiopulmonary product demand cycles
  • Clinical trial outcomes for depression and sleep apnea impact valuation
  • Supply chain stability affects manufacturing costs for heart-lung machines
  • Regulatory approval timelines for next-generation pulse generators influence market share
Piotroski VR-10 (Strict) 7.5
Net Income: 107.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.71 > 1.0
NWC/Revenue: 17.56% < 20% (prev 33.68%; Δ -16.12% < -1%)
CFO/TA 0.10 > 3% & CFO 245.6m > Net Income 107.1m
Net Debt (-149.5m) to EBITDA (232.9m): -0.64 < 3
Current Ratio: 1.33 > 1.5 & < 3
Outstanding Shares: last quarter (55.9m) vs 12m ago 2.72% < -2%
Gross Margin: 67.57% > 18% (prev 0.69%; Δ 6.69k% > 0.5%)
Asset Turnover: 56.49% > 50% (prev 49.84%; Δ 6.64% > 0%)
Interest Coverage Ratio: 3.71 > 6 (EBITDA TTM 232.9m / Interest Expense TTM 51.2m)
Altman Z'' -1.14
A: 0.10 (Total Current Assets 1.01b - Total Current Liabilities 762.5m) / Total Assets 2.52b
B: -0.45 (Retained Earnings -1.12b / Total Assets 2.52b)
C: 0.07 (EBIT TTM 190.0m / Avg Total Assets 2.54b)
D: -0.80 (Book Value of Equity -1.04b / Total Liabilities 1.30b)
Altman-Z'' = -1.14 = CCC
Beneish M -3.05
DSRI: 0.88 (Receivables 229.3m/231.4m, Revenue 1.43b/1.28b)
GMI: 1.02 (GM 67.57% / 69.02%)
AQI: 1.04 (AQ_t 0.47 / AQ_t-1 0.45)
SGI: 1.12 (Revenue 1.43b / 1.28b)
TATA: -0.06 (NI 107.1m - CFO 245.6m) / TA 2.52b)
Beneish M = -3.05 (Cap -4..+1) = AA
What is the price of LIVN shares?

As of May 27, 2026, the stock is trading at USD 75.42 with a total of 357,473 shares traded.
Over the past week, the price has changed by +4.42%, over one month by +18.94%, over three months by +6.23% and over the past year by +71.33%.

Is LIVN a buy, sell or hold?

LivaNova has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy LIVN.

  • StrongBuy: 4
  • Buy: 4
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the LIVN price?
Analysts Target Price 80.2 6.3%
LivaNova (LIVN) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 4.06b (4.06b USD * 1.0 USD.USD)
P/E Trailing = 37.6684
P/E Forward = 17.452
P/S = 2.8293
P/B = 3.3482
P/EG = 0.8432
Revenue TTM = 1.43b USD
EBIT TTM = 190.0m USD
EBITDA TTM = 232.9m USD
Long Term Debt = 285.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.60m USD (from shortTermDebt, last quarter)
Debt = 390.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 55.7m
Net Debt = -149.5m USD (calculated: Debt 390.2m - CCE 539.7m)
Enterprise Value = 3.91b USD (4.06b + Debt 390.2m - CCE 539.7m)
Interest Coverage Ratio = 3.71 (Ebit TTM 190.0m / Interest Expense TTM 51.2m)
EV/FCF = 24.25x (Enterprise Value 3.91b / FCF TTM 161.1m)
FCF Yield = 4.12% (FCF TTM 161.1m / Enterprise Value 3.91b)
FCF Margin = 11.24% (FCF TTM 161.1m / Revenue TTM 1.43b)
Net Margin = 7.47% (Net Income TTM 107.1m / Revenue TTM 1.43b)
Gross Margin = 67.57% ((Revenue TTM 1.43b - Cost of Revenue TTM 464.9m) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 66.45%)
Tobins Q-Ratio = 1.55 (Enterprise Value 3.91b / Total Assets 2.52b)
Interest Expense / Debt = 13.13% (Interest Expense 51.2m / Debt 390.2m)
Taxrate = 16.29% (4.34m / 26.6m)
NOPAT = 159.0m (EBIT 190.0m * (1 - 16.29%))
Current Ratio = 1.33 (Total Current Assets 1.01b / Total Current Liabilities 762.5m)
Debt / Equity = 0.32 (Debt 390.2m / totalStockholderEquity, last quarter 1.21b)
Debt / EBITDA = -0.64 (Net Debt -149.5m / EBITDA 232.9m)
Debt / FCF = -0.93 (Net Debt -149.5m / FCF TTM 161.1m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.22% (Net Income 107.1m / Total Assets 2.52b)
RoE = 4.67% (Net Income TTM 107.1m / Total Stockholder Equity 2.30b)
RoCE = 7.36% (EBIT 190.0m / Capital Employed (Equity 2.30b + L.T.Debt 285.2m))
RoIC = 9.74% (NOPAT 159.0m / Invested Capital 1.63b)
WACC = 9.81% (E(4.06b)/V(4.45b) * Re(9.70%) + D(390.2m)/V(4.45b) * Rd(13.13%) * (1-Tc(0.16)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 1.30%
[DCF] Terminal Value 71.97% ; FCFF base≈154.9m ; Y1≈169.2m ; Y5≈212.3m
[DCF] Fair Price = 49.86 (EV 2.59b - Net Debt -149.5m = Equity 2.74b / Shares 54.9m; r=9.81% [WACC]; 5y FCF grow 10.69% → 2.50% )
EPS Correlation: 98.07 | EPS CAGR: 16.77% | SUE: 1.04 | # QB: 1
Revenue Correlation: 99.58 | Revenue CAGR: 9.94% | SUE: 4.0 | # QB: 15
EPS current Quarter (2026-06-30): EPS=1.09 | Chg30d=-0.23% | Revisions=+33% | Analysts=10
EPS next Quarter (2026-09-30): EPS=1.08 | Chg30d=-3.97% | Revisions=-27% | Analysts=10
EPS current Year (2026-12-31): EPS=4.25 | Chg30d=+0.89% | Revisions=+67% | GrowthEPS=+8.9% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=4.64 | Chg30d=+1.39% | Revisions=+50% | GrowthEPS=+9.2% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: +67%